https://www.selleckchem.com/
001). In comparison with the control group, it remained on a higher level after the operation (p 0.001) and the next day (p = 0.03). The patients with AKI had more postoperative bleeding and received more blood transfusion. VitD pretreatment was unable to impose any changes in the incidence of AKI and the urinary level of renal biomarkers. However, high-dose administration of VitD may improve the anti-inflammatory state before and after the operation. Further studies are needed to assess the renoprotective effect of VitD on coronary surgery patients. V
Curtir
Comentario
Compartilhar
